Interní Med. 2011; 13(12): 481-486

C-peptide: from diagnosis to clinical application

MUDr.Svatopluk Solař
Interní klinika 1. LF UK a ÚVN Střešovice, Praha

C-peptide is a linker between the A- and the B- chains of insulin and, following enzymatic breakdown, is released into the circulation

as a 31-amino acid chain in an equimolar amount with insulin. Serum C-peptide level in the plasma is independent of the administration

of exogenous insulin and does not interfere with autoantibodies that are formed against it; therefore, for diagnostic purposes, its

determination is much more reliable and accurate than that of insulin. Originally used only in diagnosing, C-peptide is currently known

for its endogenous effects. C-peptide may affect the degree and extent of vascular and nervous complications, its higher level prevents

endothelial dysfunction and it also has analgesic effects. These direct and indirect effects give rise to considerations about possible

therapeutic use. In the year 2010, authorities in the field of diabetes published new recommendations for the diagnosis and screening

that reflect the global pandemic of this disease, including the incidence of morbidity, enforced disability and mortality. The review also

presents the possibilities of C-peptide utilization.

Keywords: C-peptide, insulin, diagnosis, endogenous effects, screening

Published: December 18, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Solař S. C-peptide: from diagnosis to clinical application. Interní Med. 2011;13(12):481-486.
Download citation

References

  1. Rácz O, Ništiar F, Janco A, et al. C-peptid: marker inzulinovej rezistencie. Labor Aktuell 2006; 2: 10-13.
  2. Racz O, Beňačka R, Ništiar F, et al. Diabetik - odborná príloha pre lekárov. 2004; 2: 13-18.
  3. Parita P, Allison M. Diabetes mellitus: Diagnosis and screening. Am Fam Physician, 2010; 81(7): 863-870. Go to PubMed...
  4. Steiner D, Oyer P. The biosynthesis of insulin and a probable precursor of insulin, by a human islet cell adenoma. Proc Natl Acad Sci USA. 1967; 57: 473-481. Go to original source... Go to PubMed...
  5. Šrha J, et al. Diabetologie. Praha: Galén, 2010.
  6. Pelikánová T, Bartoš V. Praktická diabetologie. Praha: Maxdorf, 2010.
  7. Perušičová J. Diabetes mellitus 2. typu - léčba hyperglykémie, dyslipidémie, hypertenze. Geum 2011.
  8. Česká diabetologická společnost. Standardy péče o diabetes mellitus 2. typu. Diabetologie, metabolismus, endokrinologie, výživa 2007; 10: 191-198.
  9. Franeková J, Jabor A. Gestační diabetes mellitus: analýza 2043 výsledků oGTT - je čas na změnu? Klin. Biochem.Metab., 2010; 39: 30-37.
  10. Anděl, et al. Diabetes mellitus a další poruchy metabolismu. Praha: Grada 2001.
  11. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33(Suppl 1): S11-S61. Go to original source... Go to PubMed...
  12. International Expert Committee. International Expert Committee report on the role of the A1c essay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-1334. Go to original source... Go to PubMed...
  13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet 1999; 354(9178): 602]. Lancet 1998; 352(9131): 837-853.
  14. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977-986.
  15. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577-1589. Go to original source... Go to PubMed...
  16. Heikes KE, Eddy DM, Arondekar B, Schlessinger L. Diabetes Risk Calculator: a simple tool for detecting undiagnosed diabetes and prediabetes. Diabetes Care 2008; 31(5): 1040-1045. Go to original source... Go to PubMed...
  17. Mochan E, Ebell M. Risk-assessment tools for detecting undiagnosed diabetes. Am Fam Physician 2009; 80(2): 175-178. Go to PubMed...
  18. Berger B, Stenström G, Sundkvist G. Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest 2000; 60(8): 687-693. Go to original source... Go to PubMed...
  19. Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48(3): 436-472. Go to original source...
  20. Sabbah E, Savola K, Kulmala P, et al. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes in Finland Study Group. J Clin Endocrinol Metab 1999; 84(5): 1534-1539. Go to original source...
  21. Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999; 48(1): 150-157. Go to original source... Go to PubMed...
  22. Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to isletcell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group [published correction appears in Lancet. 1998; 351(9099): 376]. Lancet 1997; 350(9087): 1288-1293. Go to original source... Go to PubMed...
  23. Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71) [published correction appears in Diabetologia. 2005; 48(6): 1240]. Diabetologia 2005; 48(4): 703-708. Go to original source... Go to PubMed...
  24. Törn C, Landin-Olsson M, Ostman J, et al. Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as type 1 diabetes on clinical grounds. Diabetes Metab Res Rev 2000; 16(6): 442-447. Go to original source... Go to PubMed...
  25. Savola K, Bonifacio E, Sabbah E, et al. IA-2 antibodies - a sensitive marker of IDDM with clinical onset in childhood and adolescence. Childhood Diabetes in Finland Study Group. Diabetologia 1998; 41(4): 424-429. Go to original source... Go to PubMed...
  26. Davis TM, Wright AD, Mehta ZM, et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 2005; 48(4): 695-702. Go to original source... Go to PubMed...
  27. Maclaren N, Lan M, Coutant R, et al. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (type 1) diabetes in relatives. J Autoimmun 1999; 12(4): 279-287. Go to original source... Go to PubMed...
  28. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the management of diabetes mellitus. http://www.aace.com/pub/pdf/guidelines/DMGuidelines2007.pdf. Accessed July 8, 2009.
  29. Feig DS, Palda VA, Lipscombe L. Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2005; 172(2): 177-180. Go to original source... Go to PubMed...
  30. U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults. Recommendation statement. June 2008. http://www.ahrq.gov/clinic/uspstf08/type2/type2rs.htm#clinical. Accessed July 8, 2009.
  31. Committee on Obstetric Practice. ACOG Committee Opinion No. 435: postpartum screening for abnormal glucose tolerance in women who had gestational diabetes mellitus. Obstet Gynecol 2009; 113(6): 1419-1421. Go to original source... Go to PubMed...
  32. American College of Obstetricians and Gynecologists Committee on Practice Bulletins - Obstetrics. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces technical bulletin number 200, December 1994). Gestational diabetes. Obstet Gynecol 2001; 98(3): 525-538. Go to PubMed...
  33. Canadian Task Force on Preventive Health Care. Summary table of recommendations. Sreening for gestational diabetes mellitus. http://www.ctfphc.org/Tables/Ch02tab.htm. Accessed January 18, 2010.
  34. U.S. Preventive Services Task Force. Screening for gestational diabetes mellitus. Recommendation statement. May 2008. http://www.ahrq.gov/clinic/uspstf08/gestdiab/gdrs.htm. Accessed January 18, 2010.
  35. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999; 354(9179): 617-621.
  36. Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008; 336(7654): 1180-1185. Go to original source... Go to PubMed...
  37. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement [published correction appears in Ann Intern Med 2008; 149(2): 147]. Ann Intern Med 2008; 148(11): 846-854.
  38. Crowther CA, Hiller JE, Moss JR, et al. for the Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352(24): 2477-2486. Go to original source... Go to PubMed...
  39. Palmer JP, Hampe CS, Chiu H, et al. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 2005; 54(Suppl 2): S62-S67. Go to original source... Go to PubMed...
  40. Expert committee of the diagnosis and classification of diabetes mellitus. Report of the Expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
  41. Česká společnost klinické biochemie a Česká diabetologická společnost. Laboratorní diagnostika a sledování stavu diabetes mellitus. Diabetologie, metabolismus, endokrinologie, výživa, 2007; 10: 232-241.
  42. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care, 2008; 31: 1473-1478. Go to original source... Go to PubMed...
  43. Jeppson Jo, Kobold U, Barr J, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med, 2002; 40: 78-89. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.